Description

NSE announces web-based bidding platform availability for Nectar Lifesciences Limited's buyback offer of up to 3 crore equity shares at Rs. 27 per share under the Tender Offer scheme.

Summary

Nectar Lifesciences Limited will conduct a buyback offer under the Tender Offer scheme using NSE’s web-based bidding platform. The company will buy back up to 3,00,00,000 equity shares at Rs. 27 per share. All Capital Market segment trading members are eligible to participate in the facility.

Key Points

  • Buyback of up to 3 crore equity shares of Nectar Lifesciences Limited
  • Fixed offer price: Rs. 27 per equity share
  • Face value: Re. 1 per share
  • Lot size: 1 equity share
  • ISIN: INE023H01027
  • Security symbol: NECLIFE (Series: BB)
  • Merchant Banker: Master Capital Services Limited
  • Registrar: KFin Technologies Limited
  • Trading members can use existing IPO bidding platform credentials
  • New users can access via admin terminal (Adminxxxxx format where xxxxx is Member Code)

Regulatory Changes

No regulatory changes. This circular implements the existing Tender Offer Scheme framework as per NSE circular NSE/CMTR/52776 dated June 29, 2022.

Compliance Requirements

  • Trading members must use the web-based bidding platform at https://eipo.nseindia.com
  • Members without existing access must log in to admin terminal to create branches and users
  • Custodial confirmation must be completed within specified timings
  • All bidding categories must follow designated status codes (FII, MF, IC, FI, OTH, CO, IND, NOH)

Important Dates

  • Issue Period: December 31, 2025 to January 6, 2026
  • Bidding Time: 9:15 AM to 3:30 PM daily
  • Custodial Confirmation: 9:15 AM to 4:00 PM (extended to 4:00 PM on issue closure date)

Impact Assessment

This buyback offer impacts shareholders of Nectar Lifesciences Limited who wish to participate in the tender offer. The buyback provides an exit opportunity at Rs. 27 per share. Trading members need to ensure system access and user credentials are configured before the issue period begins on December 31, 2025. Eight investor categories are eligible to participate, including FIIs, mutual funds, insurance companies, banks, financial institutions, QIBs, bodies corporate, individuals, and other non-institutional investors.

Impact Justification

Company-specific buyback offer affecting shareholders of Nectar Lifesciences Limited. Moderate impact limited to single stock with standard buyback procedure through NSE platform.